The genes in this signature included several with higher prevalence in one molecular subtype (ABC DLBCL vs. GCB DLBCL) than the other (e.g., TNFAIP3, CD58, PRDM1, and CBL in ABC DLBCL and MYST3, CREBBP, SGK1, PARP4, and PDCD11 in GCB DLBCL) (Fig. 4b, Supplementary Fig. 2), as well as several genes with known prognostic significance in DLBCL (TNFAIP3, CD58, CREBBP, and PRDM1). The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.